From: s47F To: S Cc:

;s47F

Subject: RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Date: Tuesday, 22 October 2019 1:00:31 PM

image002.png image003.png **Attachments:**

image004.png image005.png image006.png Sensitivity analyses.docx

Hi **s22**

Please find additional sensitivity analyses attached.

s47E(d), s47, s47C, s47G, s38

DOLINE HELD ON ARTHUR DE PARTINE DE LA PROPERTIE DE LA PRIMERIO DEL PRIMERIO DE LA PRIMERIO DE LA PRIMERIO DE LA PRIMERIO DE LA PRIMERIO DEL PRIMERIO DE LA PRIMERIO DEL PRIMERIO DEL PRIMERIO DE LA PRIMERIO DEL PRIMERIO DEL PRIMERIO DEL PRIMERIO DEL PRIMERIO DE LA PRIMERIO DEL PRIMERIO DEL

s47F

s47F

s47F

s47F

FOI 1810 1 of 4



From: s47F

Sent: Tuesday, 22 October 2019 10:51 AM

To: \$2 Cc: \$22

s47F

Subject: RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Hi **s22**

We are working on this and will send a response when we can.

Cheers, s47F

s47F s47F

s47F

s47F

From: \$22

Sent: Monday, 21 October 2019 8:59 PM

To: \$47F Cc: \$22

Subject: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Importance: High

His47F

As mentioned at the ESC meeting, s47E(d), s47, s47C, s47G, s38

FOI 1810 2 of 4

Can you let me know whether the analysis can be done? If possible could you please let me know by mid-morning Tuesday (sorry – we're trying to finalise the ESC ADV!).

Many thanks, **S47F**!

Kind regards,

s22

PBAC Secretariat

Office of Health Technology Assessment | Technology Assessment & Access Division Australian Government Department of Health

s22

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissernination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

FOI 1810 3 of 4

DCUMERIE DEPARTMENT OF HER THE DEPARTMENT OF